Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants | Zendy

AI Assistant Blog Pricing

Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.